N4-Behenoy1-1-β-D-arabinofuranosy1cytosine (BH-AC) was administered to 11 patients with acute leukemia and five patients with other malignancies in a Phase I and TI clinical trial. Among 16 patients, 14 received BH-AC after being refractory to prior therapies, and two with acute leukemia received BH-AC for their first remission induction therapy.The starting dose was 1.5mg/kg administered as a single i.v. infusion of three hours. The doses were then escalated up to 5.0 mg/kg. No side effects were noted with single i.v. infusions. Daily consecutive infusions of 2.0 mg to 6.0 mg/kg for four to 21 days resulted in two patients experiencing nausea, two anorexia and one developing skin eruptions. Significant hematological effects were noted by the daily infusions. One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC administered daily for 21 days.BH-AC is active in acute leukemia and may play a role in the combination regimens for this disease.
|Number of pages||8|
|Journal||Japanese journal of clinical oncology|
|Publication status||Published - Dec 1978|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cancer Research